A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs LND 101001 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Lupin
  • Most Recent Events

    • 14 Dec 2016 This trial has been completed in Croatia (end date: 29 Aug 2016).
    • 30 Nov 2016 This trial has been completed in Poland (End date:2016-08-29) as per European Clinical Trials Database record.
    • 02 Oct 2016 This trial has been completed in Spain (End date:2016-08-29) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top